Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.

Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.

Alvotech has once again raised more than $100m in financing, the second time in a matter of months, via a private placement involving what it expects to be previously issued treasury shares held by one of its subsidiaries.